Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis

August 2023 | Volume 22 | Issue 8 | 779 | Copyright © August 2023


Published online July 10, 2023

Margaret Bobonich DNP FNP-C DCNP FAANPa, Joe Gorelick MSN FNP-Cb, Lakshi Aldredge MSN ANP-BC DCNP FAANPc, Matthew J. Bruno PA-Cd, Douglas DiRuggiero DMSc MHS PA-Ce, George Martin MDf, Anna M. Tallman PharmDg, Linda Stein Gold MDh

aDepartment of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH
bDepartment of Dermatology, California Skin Institute, San Jose, CA
cDermatology Service, Operative Care Division, VA Portland Healthcare System, Portland, OR
dClinical Development, Dermatology & Skin Cancer Surgery Center, Allen, TX
eDermatology, Skin Cancer & Cosmetic Dermatology Center, Rome, GA
fDermatology, George Martin Dermatology Associates, Kihei, HI
gMedical Affairs, Dermavant Sciences, Inc., Morrisville, NC
hDepartment of Dermatology, Henry Ford Health System, Detroit, MI

Lakshi Aldredge has served as a speaker and/or consultant and/or involved in advisory boards for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant Sciences Inc, Eli Lilly, Incyte, Janssen, Leo Pharma, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB Biopharma.

Matthew J. Bruno has served as a consultant, and/or received payment for promotional presentations from AbbVie, Almirall, Bristol Myers Squibb, Dermavant Sciences, Inc., EPI Health, Journey Medical Corporation, Mayne Pharma, Medimetriks Pharmaceuticals, Pfizer, Regeneron/Sanofi-Genzyme, and Sun Pharmaceuticals.

Douglas DiRuggiero has served as a speaker and/or has been involved in advisory boards for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, EPI Health, Eli Lilly, Incyte, Novartis, Regeneron, Sanofi, Sun Pharmaceuticals, and UCB Biopharma.

George Martin has served as a speaker and/or consultant and/or has been involved in scientific advisory boards for AbbVie, Almirall, Arcutis, Biofrontera, Bristol Myers Squibb, Dermavant Sciences, Inc., DUSA/SUN, Eli Lilly, Evelo, Galderma, Horizon, Incyte, Janssen, LEO Pharma, Ortho/Bausch Health, Organogenesis, Pfizer, Sanofi/Regeneron, Trevi, and UCB Biopharma.

Anna M. Tallman is an employee of Dermavant Sciences Inc., with stock options.

Linda Stein Gold has served as a consultant, and/or has received payment for the development of educational presentations, and/or has received grants from Amgen, Arcutis, Bristol Myers Squibb, Dermavant Sciences, Inc., Eli Lilly, LEO Pharma, Ortho Dermatologics, Pfizer, and UCB Biopharma.

Funding: Manuscript preparation and editorial assistance were funded by Dermavant Sciences, Inc.

ACKNOWLEDGEMENTS

Medical writing and editorial support under the guidance of the authors was provided by Julia Burke PhD, of ApotheCom, UK, and was funded by Dermavant Sciences, Inc., in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2022;175:1298-1304). 

REFERENCES

  1. Parisi R, Iskandar IY, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590
  2. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70:871-881.e30.
  3. Armstrong AW, Mehta MD, Schupp CW, et al. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157:940-946.
  4. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826-850.
  5. Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.
  6. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58:1031-1042.
  7. Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003–2011. PloS one. 2012;7:e52935.
  8. Feldman SR, Goffe B, Rice G, et al. The challenge of managing psoriasis: unmet medical needs and stakeholder perspectives. Am Health Drug Benefits. 2016;9:504-513.
  9. Elmets CA, Lim HW, Stoff B, et al. Joint American Academy of Dermatology- National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. J Am Acad Dermatol. 2019;81:775- 804.
  10. Enos CW, O'Connell KA, Harrison RW, et al. Psoriasis severity, comorbidities, and treatment response differ among geographic regions in the United States. JID Innov. 2021;1:100025.
  11. Elmets CA, Korman NJ, Prater EF, et al. Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021;84:432-470.
  12. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029-1072.
  13. Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82:1445-1486.
  14. Eicher L, Knop M, Aszodi N, et al. A systematic review of factors influencing treatment adherence in chronic inflammatory skin disease – strategies for optimizing treatment outcome. J Eur Academy Dermatol Venereol. 2019;33:2253-2263.
  15. Aldredge LM, Higham RC. Manifestations and management of difficult-totreat psoriasis. J Dermatol Nurses Assoc. 2018;10:189-197.
  16. Callis Duffin K, Yeung H, Takeshita J, et al. Patient satisfaction with treatments for moderate‐to‐severe plaque psoriasis in clinical practice. Br J Dermatol. 2014;170:672-680.
  17. Bissonnette R, Gold LS, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84:1059-1067.
  18. Uva L, Miguel D, Pinheiro C, et al. Mechanisms of action of topical corticosteroids in psoriasis. Int J Endocrinol. 2012;2012:561018.
  19. Pardasani AG, Feldman SR, Clark AR. Treatment of psoriasis: an algorithmbased approach for primary care physicians. Am Fam Physician. 2000;61:725- 733.
  20. Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137:2110-2119.
  21. Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI- 1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26:1516-1521.
  22. Lebwohl MG, Stein Gold L, Strober B, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385:2219-2229.
  23. Esser C, Rannug A. The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev. 2015;67:259-279.
  24. Furue M, Tsuji G, Mitoma C, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci. 2015;80:83-88.
  25. Esser C, Rannug A, Stockinger B. The aryl hydrocarbon receptor in immunity. Trends Immunol. 2009;30:447-454.
  26. Negishi T, Kato Y, Ooneda O, et al. Effects of aryl hydrocarbon receptor signaling on the modulation of TH1/TH2 balance. J Immunol. 2005;175:7348- 7356.
  27. Strober B, Stein Gold L, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87:800-806.
  28. Dermavant Sciences Inc. Dermavant announces first patient dosed in ADORING, its pivotal phase 3 clinical program for tapinarof for the topical treatment of atopic dermatitis. September 9, 2021. Available at: https:// www.dermavant.com/dermavant-announces-first-patient-dosed-in-adoring/. Accessed December 20, 2022.
  29. Lebwohl M, Stein Gold L, Strober B, et al. Tapinarof cream 1% QD for the treatment of plaque psoriasis: efficacy and safety in two pivotal phase 3 trials. SKIN J Cutan Med. 2020;4:s75.
  30. Stein Gold L, Blauvelt A, Armstrong A, et al. Tapinarof cream 1% once daily for plaque psoriasis: secondary efficacy outcomes from two pivotal phase 3 trials. Presented at The 6th World Psoriasis & Psoriatic Arthritis Conference; June 30–July 3, 2021; Virtual.
  31. Kircik L, Stein Gold L, Del Rosso J, et al. Tapinarof cream 1% once daily for plaque psoriasis: efficacy by baseline disease characteristics and demographics in two pivotal phase 3 trials. Presented at 2021 Fall Clinical Dermatology Conference; November 12–14, 2021; Orlando, FL, USA.
  32. Bissonnette R, Strober B, Lebwohl M, et al. Tapinarof cream 1% once daily for plaque psoriasis: patient-reported outcomes from two pivotal phase 3 trials. Presented at The 6th World Psoriasis & Psoriatic Arthritis Conference; June 30–July 3; 2021; Virtual.
  33. Armstrong AW, Desai SR, Gooderham M, et al. Tapinarof cream 1% once daily for plaque psoriasis: dermatology life quality index and local tolerability scores from a long-term extension trial. Presented at the Annual Academy of Dermatology Association Meeting; March 25–29, 2022; Boston, MA, USA.
  34. Jett JE, McLaughlin M, Lee MS, et al. Tapinarof cream 1% for extensive plaque psoriasis: A maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2021;23:83-91.
  35. Bissonnette R, Gold LS, Rubenstein DS, et al. Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapy. J Am Acad Dermatol. 2021;85:e39-e40.
  36. Bagel J, Gold LS, Del Rosso J, et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023;S0190-9622(23)00771-5. doi: 10.1016/j.jaad.2023.04.061.
  37. Dermavant Sciences. VTAMA® (tapinarof) cream, 1%: US prescribing information. 2022. Available at: https://www.vtama.com/docs/DMVT_ VTAMA_PI.pdf. Accessed December 20, 2022.
  38. Gutiérrez-Vázquez C, Quintana FJ. Regulation of the immune response by the aryl hydrocarbon receptor. Immunity. 2018;48:19-33.

AUTHOR CORRESPONDENCE

Margaret Bobonich DNP FNP-C DCNP FAANP mbobonich@aol.com
Close Menu